SGX Pharmaceuticals, a biotechnology company developing novel cancer therapeutics, lowered its range to $7 to $8 from $11 to $13 Wednesday morning. The offering size remains unchanged at 4.0 million shares. CIBC World Markets and Piper Jaffray are the joint book runners on the deal. The stock is scheduled to price tonight and begin trading on the NASDAQ tomorrow under the symbol "SGXP."
